Pfizer: Obesity Hype And Vaccine Policy Shocks (Archive)

This 5-Minute Pitch was originally published on Seeking Alpha before the launch of the Hunting Alphas website. It is shared here to showcase my previous work and track record. New 5-Minute Pitches published on this site will not be disseminated anywhere else.

Elevator Pitch

• Pfizer's obesity drug pipeline is lagging leaders and faces safety concerns, increasing the risk that revenue targets from acquisitions, like Metsera, will be missed.
• Recent U.S. childhood vaccine schedule cuts, especially narrowing RSV recommendations, create a modest revenue headwind for the company's vaccine portfolio via Abrysvo.
• PFE is ramping up pivotal trials in obesity and oncology, but rising R&D intensity is pressuring earnings and driving downward revisions to normalized EPS estimates.
• Despite trading at a steep forward P/E discount to pharmaceutical peers, flat earnings expectations and valuation drivers leave limited clear catalysts for Pfizer's share price.
• After a short-lived relative rally vs. the S&P 500, PFE's price is stalling at resistance, and technicals suggest renewed underperformance risk.

Read the full article here.